Companies › GuangZhou Cellgenes Biotechnology
1 active drug program in 2 registered trials: 2 Phase 1; Neurology, Other; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CG-BM1 Allogeneic human bone marrow mesenchymal stem cell injection | – | Phase 1 | Ischemic Stroke or High-risk TIA (ABCD² ≥ 4); Sarcopenia | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07896941 | CG-BM1 | Phase 1 | Ischemic Stroke or High-risk TIA (ABCD² ≥ 4) | Neurology | Dec 2028 |
| NCT07865676 | CG-BM1 | Phase 1 | Sarcopenia | Other | Jun 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.